Statins are arguably the most efficacious lipid-lowering drugs available. Many benefits are now considered to emerge from pleiotropic effects other than lipid modification. Novack and coauthors have reported yet another positive lipid effect of statins.1 Researchers who analyzed the results of the JUPITER trial also showed that rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism.2 However, the United States Food and Drug Administration (FDA) has recently approved a new safety labelling change for the entire class of drug.3 The FDA has warned that increases in glycosylated hemoglobin (HbA1c) and fasting serum glucose levels have been reported with statin use. Moreover, the FDA has added a safety warning about associated cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion).3 We have to bear in mind that statins have numerous interactions with cardiovascular and other drugs that may increase the toxicity of statins.3,4